Is This a Registered Study, and What Exactly Are You Paying For?

Published 9 min read

Document links
5
Quoted passages
7
Fact-checked
18 September 2026
Reviewed
every six months

Sources on this page: www.fda.gov · clinicaltrials.gov

Is This a Registered Study, and What Exactly Are You Paying For?

Two questions, and they are not the same question.

Being described as a study does not make something a registered study. Being a registered study does not make it free. Collapsed into one, they hide the part that matters.

This page separates them and shows you how to check each.

Two separate questions

Question one: is there a registry record? This has a yes or no answer and you can verify it yourself.

Question two: what precisely is being charged, and for what? This has a written answer, or it does not, and that is informative either way.

A situation can be a registered study with costs attached. It can be an unregistered treatment offered free. Neither combination is impossible, so asking one question does not answer the other.

Find the registration number

A registered study has an identifier, but the identifier belongs to a particular registry and there is more than one registry in the world. A study registered on ClinicalTrials.gov receives a number written as NCT followed by digits, and that is the register this page describes, because it is the one this field points people to. A number in a different format belongs to a different register, and you will need to know which one before you can look anything up.

So ask for two things rather than one: which registry, and what identifier in it. The number may appear on a consent document, on a website, or in materials you have been given. The registry name may not appear alongside it, and without the registry name the number does not identify anything.

If you are told this is a study and no identifier can be produced at all, that is a finding. Registration requirements depend on the type of study, so an absent number does not automatically mean no study exists. It does mean the public record you could have checked is not available to you, and you should ask directly why.

The rest of this page describes a ClinicalTrials.gov record specifically. If you are given a different registry, the sections below may not map onto it, and the register’s own site is the place to find out what its records contain.

What a registry record actually contains

A record is organised into sections. These are the ones that answer a patient’s questions.

Identification. The NCT number and the study title.

Status. Whether the study is recruiting, active, completed or has stopped.

Sponsor and collaborators. Who is running it. The record carries a class for the lead sponsor, so you can see what kind of organisation it is rather than only its name.

Oversight. Whether the study falls under particular regulatory oversight.

Design. Study type, for example interventional or observational, and phase where applicable.

Enrollment. A number, and importantly a flag stating whether it is the actual figure or an estimate. A study still recruiting shows a target, not a result.

Eligibility. Who could take part: criteria, sex, minimum and maximum age.

Outcome measures. What the study set out to measure, listed as primary and secondary.

Contacts and locations. Where it is being run and who to reach.

Those sections are the check. Compare the study title and the eligibility section against what is being offered to you. If the record describes something different from what you are being told, write down both versions. That difference is the finding.

What a registry listing does and does not mean

Four distinctions, and they get merged into one.

A registry listing is not FDA approval. These are separate systems. Registration records that a study exists. Approval is a decision about a product after review.

A registry listing does not by itself establish FDA oversight. Some studies are conducted under regulatory oversight and some are not; the record has a field for this, which is precisely why the listing alone does not settle it. Look at the field rather than inferring from the presence of a record.

A registry listing is not a scientific endorsement. Records are submitted by those running the study. Being listed is not a finding that a study is well designed or that its rationale is sound.

A registry listing is not a statement that marketing around it is lawful. The FDA has addressed this pattern directly:

“patients and consumers are being referred to clinicaltrials.gov, or are told that a product is registered with FDA, as a way to suggest that the products being offered are in compliance with FDA laws and regulations. This is often false.”

Source: FDA, Important Patient and Consumer Information About Regenerative Medicine Therapies. Accessed 18 September 2026.

What “IRB-approved” tells you, and what it does not

An institutional review board is a human-subject protection body, and FDA’s own description of what an investigational application commits a sponsor to shows exactly where it sits. Among those commitments:

“commitments to obtain informed consent from the research subjects, to obtain review of the study by an institutional review board (IRB), and to adhere to the investigational new drug regulations”

Source: FDA, Investigational New Drug (IND) Application. Accessed 18 September 2026.

Read what that sentence puts side by side: consent, IRB review, and the regulations. Three separate obligations, listed together, and not one of them is a finding about whether the treatment works.

That is the distinction this section exists for: a protections review and an effectiveness finding are different objects. A study can have proper ethical review and still be testing something that turns out not to help anyone; that is what studies are for. So “IRB-approved” is not a synonym for “works”, and it is not a product approval either.

What we did not open: the regulation setting out an IRB’s composition, authority and duties in full. So this page does not describe its complete remit, and it cannot tell you what any particular board reviewed.

If a clinic offers IRB approval as its answer to an effectiveness question, the useful reply is to ask the effectiveness question again, separately. And if you want to know what the board actually reviewed and under what authority, ask for the board’s name and the protocol number; those two facts make the question answerable by someone other than the party offering the treatment.

One more question the registry record does not answer

Three things are worth establishing about a listing: who the sponsor is, whether there is an IRB, and whether the study runs under an FDA investigational application, the mechanisms written as IND for a biological or drug product and IDE for a device. The record described above answers the first two. It does not answer the third.

An IND is an application to FDA, and FDA describes what it is for:

“A physician might submit a research IND to propose studying an unapproved drug, or an approved product for a new indication or in a new patient population.”

There is also a category specifically for treatment rather than study:

“Treatment IND is submitted for experimental drugs showing promise in clinical testing for serious or immediately life-threatening conditions while the final clinical work is conducted and the FDA review takes place.”

Source for both: FDA, Investigational New Drug (IND) Application. Accessed 18 September 2026.

But “no application” is not automatically a finding, and this is the part to get right. Not every study needs one, and FDA says so on both sides.

For drugs:

“Generally, a clinical investigation of a marketed drug is exempt from the IND requirements if all of the criteria for an exemption under 21 CFR 312.2(b)(1) are met: The drug product is lawfully marketed in the United States…”

For devices, the level of oversight depends on risk:

“A nonsignificant risk device study requires only IRB approval prior to initiation of a clinical study. Sponsors of studies involving nonsignificant risk devices are not required to submit an IDE application to the FDA for approval.”

Source for both: FDA, “IND Application Procedures: Exemptions from IND Requirements” and “IDE Approval Process.” Accessed 18 September 2026.

So there is more than one lawful answer, and the question has to be wide enough to let a correct one through. Ask it like this: is this study conducted under an IND, under an IDE, under an exemption, or on some other regulatory basis; and if there is an IND or IDE, what is the number?

A number is checkable. “An exemption applies” is an answer too, and the follow-up is which exemption, and on what basis. What would not be an answer is a change of subject.

One more thing follows from the treatment category above. It is why our page on the document you sign has three boxes rather than two: investigational products do get provided for treatment, under rules, and that is a different situation from both a trial and ordinary treatment paperwork.

What we did not open: the regulations themselves. So this page does not set out what an application requires, what an exemption requires, or what follows in law from any particular answer. What it gives you is a question shaped so that none of the lawful answers is excluded.

What FDA says about being charged

This is the strongest published statement in this area, and its scope has to travel with it.

“if you are being charged for these products or offered these products outside of a clinical trial, you are likely being deceived and offered a product illegally.”

Source: FDA, Important Patient and Consumer Information About Regenerative Medicine Therapies. Accessed 18 September 2026.

Scope of this quotation. This sentence appears on an FDA page about unapproved regenerative medicine products and describes that class. FDA approved products are outside it. So the sentence does not say that paying for treatment in this field is always a problem. It says something specific about a specific category, and establishing which category you are in is the prior step.

That is the reason the approval question comes before this one.

Ask for an itemised answer

Whatever the answer to question one, question two stands on its own.

Ask what the charge covers: the product, the procedure, imaging, facility, follow-up. Ask whether any part of it relates to study participation rather than treatment. Ask for it in writing.

An itemised written answer lets you see the shape of what you are buying. A single figure does not, whether it is large or small.

Where to go from here

If there is a registry record, the next step is reading what it says rather than noting that it exists: Reading the Study a Clinic Shows You. If the approval status of the product is still unclear, that question sits underneath this one, in What Is and Is Not FDA Approved in Regenerative Medicine.

Before you leave this page: ask for the registry name and its identifier, and for the itemised charge, all in writing. They are single requests and all of them are checkable later.

What this does not mean

This page does not say that paid treatment is improper or that registered studies are safe. It does not tell you whether to take part in anything. It describes two separate checks and what each one can establish. Whether any study or treatment is suitable for you is a clinical question for a qualified professional who knows your history.

Official sources cited on this page. Every quotation above is taken from one of these. If one of them has changed since we read it, this page is the thing that is out of date, not the record.

Written and fact-checked against the sources above on 18 September 2026. No independent expert review has taken place yet, and this page says so rather than implying one. This page is reviewed every six months.

Leave a comment

Your email address will not be published. Required fields are marked *